State Of Alaska Department Of Revenue Decreased Western Un Co (WU) Stake By $536,560; Orbimed Advisors Lowered Array Biopharma (ARRY) Holding

June 8, 2018 - By Louis Casey

The Western Union Company (NYSE:WU) Logo

State Of Alaska Department Of Revenue decreased Western Un Co (WU) stake by 23.88% reported in 2018Q1 SEC filing. State Of Alaska Department Of Revenue sold 28,240 shares as Western Un Co (WU)’s stock declined 1.48%. The State Of Alaska Department Of Revenue holds 90,016 shares with $1.73M value, down from 118,256 last quarter. Western Un Co now has $9.57B valuation. The stock decreased 0.81% or $0.17 during the last trading session, reaching $20.78. About 3.70M shares traded. The Western Union Company (NYSE:WU) has risen 3.57% since June 8, 2017 and is uptrending. It has underperformed by 9.00% the S&P500. Some Historical WU News: ; 01/05/2018 – Western Union 1Q EPS 46c; 01/05/2018 – Western Union lifts guidance as online drive pays off; 07/05/2018 – Western Union Presenting at JPMorgan Conference May 15; 21/03/2018 – Western Union rival TransferWise says it will record its second year of profit; 01/05/2018 – Western Union 1Q Net $213.6M; 01/05/2018 – Western Union Sees 2018 GAAP Effective Tax Rate of Approximately 14%, Adjusted Tax Rate of Approximately 15%; 01/05/2018 – WESTERN UNION SEES FY ADJ EPS $1.80 TO $1.90; 01/05/2018 – Western Union Sees FY Adj EPS $1.80-Adj EPS $1.90; 21/05/2018 – Western Union Business Solutions Launches Intl Business Development Program With United Bankers’ Bank; 21/05/2018 – Western Union Business Solutions Launches International Business Development Program with United Bankers’ Bank

Orbimed Advisors Llc decreased Array Biopharma Inc (ARRY) stake by 35.7% reported in 2018Q1 SEC filing. Orbimed Advisors Llc sold 2.72M shares as Array Biopharma Inc (ARRY)’s stock declined 10.53%. The Orbimed Advisors Llc holds 4.90M shares with $79.98M value, down from 7.62M last quarter. Array Biopharma Inc now has $3.74 billion valuation. The stock decreased 0.45% or $0.08 during the last trading session, reaching $17.77. About 2.08 million shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 92.14% since June 8, 2017 and is uptrending. It has outperformed by 79.57% the S&P500. Some Historical ARRY News: ; 08/05/2018 – OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of lmmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer; 03/05/2018 – European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo Plus Yervoy Combination; 09/05/2018 – ARRAY BIOPHARMA 3Q LOSS/SHR 11C, EST. LOSS/SHR 23C; 15/04/2018 – Merck: Safety Profile of Keytruda Consistent With Previous Trials of Patients With Advanced Melanoma; 23/04/2018 – EUROPEAN MEDICINES AGENCY VALIDATES TYPE Il VARIATION FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH PEMETREXED (ALIMTA®) AND PLATINUM CHEMOTHERAPY AS FIRST-LINE THERAPY IN METASTATIC…; 09/04/2018 – STAT Plus: With positive Keytruda data, Merck scrambles the market for lung cancer immunotherapies; 26/04/2018 – Bristol-Myers’ cancer drug Opdivo fuels growth, but revenue falls short; 18/05/2018 – FDA ISSUES ALERT ON ISSUE FOUND IN TRIALS ON KEYTRUDA,TECENTRIQ; 13/04/2018 – BRISTOL-MYERS SQUIBB- IN TRIAL, TWO SECONDARY ENDPOINTS OF ORR, MEDIAN DURATION OF RESPONSE DEMONSTRATED DURABILITY WITH OPDIVO VS DOCETAXEL; 18/04/2018 – U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously

Analysts await Array BioPharma Inc. (NASDAQ:ARRY) to report earnings on August, 8. They expect $-0.25 earnings per share, down 47.06% or $0.08 from last year’s $-0.17 per share. After $-0.11 actual earnings per share reported by Array BioPharma Inc. for the previous quarter, Wall Street now forecasts 127.27% negative EPS growth.

Among 10 analysts covering Array BioPharma (NASDAQ:ARRY), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Array BioPharma had 39 analyst reports since June 3, 2016 according to SRatingsIntel. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Jefferies on Monday, August 29. The stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Mkt Perform” rating given on Monday, January 30 by Leerink Swann. The rating was maintained by Piper Jaffray with “Overweight” on Monday, September 26. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Outperform” rating by Leerink Swann on Monday, January 22. Cantor Fitzgerald maintained it with “Buy” rating and $1300 target in Tuesday, May 30 report. The company was maintained on Tuesday, July 18 by Cantor Fitzgerald. Cowen & Co maintained the shares of ARRY in report on Tuesday, June 5 with “Buy” rating. As per Wednesday, August 9, the company rating was maintained by Cantor Fitzgerald. Cantor Fitzgerald maintained Array BioPharma Inc. (NASDAQ:ARRY) rating on Monday, September 11. Cantor Fitzgerald has “Overweight” rating and $15 target. The rating was maintained by Cowen & Co on Wednesday, February 7 with “Buy”.

Orbimed Advisors Llc increased Gw Pharmaceuticals Plc (NASDAQ:GWPH) stake by 29,600 shares to 74,000 valued at $8.34 million in 2018Q1. It also upped Bristol Myers Squibb Co (NYSE:BMY) stake by 2.99 million shares and now owns 3.68M shares. Vertex Pharmaceuticals Inc (NASDAQ:VRTX) was raised too.

Since December 16, 2017, it had 0 buys, and 10 sales for $16.60 million activity. Another trade for 7,500 shares valued at $102,975 was made by Haddock Jason on Tuesday, January 16. Shares for $3.03M were sold by Robbins Andrew R. $368,940 worth of Array BioPharma Inc. (NASDAQ:ARRY) was sold by VAN LUNSEN GIL J on Wednesday, February 21. Squarer Ron sold $8.90M worth of Array BioPharma Inc. (NASDAQ:ARRY) on Saturday, December 16. Shares for $2.76 million were sold by Sandor Victor.

More news for Array BioPharma Inc. (NASDAQ:ARRY) were recently published by: Fool.com, which released: “3 Biotechs With Huge FDA Decisions in June” on May 31, 2018. Nasdaq.com‘s article titled: “George Soros Bought This Clinical-Stage Biotech Stock. Should You?” and published on May 31, 2018 is yet another important article.

Investors sentiment increased to 1.74 in 2018 Q1. Its up 0.44, from 1.3 in 2017Q4. It is positive, as 16 investors sold ARRY shares while 54 reduced holdings. 55 funds opened positions while 67 raised stakes. 189.71 million shares or 2.27% less from 194.11 million shares in 2017Q4 were reported. Mackay Shields Ltd Llc stated it has 0.01% in Array BioPharma Inc. (NASDAQ:ARRY). California State Teachers Retirement Systems reported 303,200 shares. Raymond James Fincl Advsr invested 0% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY). 683 Management Ltd owns 450,000 shares or 0.65% of their US portfolio. Tiaa Cref Mngmt Lc stated it has 0.01% in Array BioPharma Inc. (NASDAQ:ARRY). Blackrock has 15.95 million shares for 0.01% of their portfolio. Wellington Gru Limited Liability Partnership stated it has 0% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY). Panagora Asset holds 0.08% or 1.18 million shares. Clarivest Asset Limited Co stated it has 200,581 shares. Bb&T Secs Ltd Liability has 190,800 shares for 0.04% of their portfolio. Ameriprise Financial Inc accumulated 230,326 shares. Weiss Multi, a Alabama-based fund reported 140,000 shares. & Management Grp owns 134,751 shares. Shell Asset Mgmt reported 0.01% of its portfolio in Array BioPharma Inc. (NASDAQ:ARRY). Victory owns 65,040 shares or 0% of their US portfolio.

Among 19 analysts covering The Western Union Company (NYSE:WU), 3 have Buy rating, 7 Sell and 9 Hold. Therefore 16% are positive. The Western Union Company has $2300 highest and $15.50 lowest target. $19.94’s average target is -4.04% below currents $20.78 stock price. The Western Union Company had 38 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Underweight” rating given on Friday, August 14 by JP Morgan. Northland Capital maintained the stock with “Hold” rating in Wednesday, October 11 report. The stock has “Sell” rating by Goldman Sachs on Thursday, December 14. Monness Crespi & Hardt downgraded it to “Neutral” rating and $22 target in Thursday, September 8 report. The firm has “Underweight” rating by Morgan Stanley given on Friday, November 3. On Wednesday, February 14 the stock rating was maintained by Susquehanna with “Hold”. The rating was downgraded by Susquehanna to “Negative” on Monday, September 19. The firm has “Hold” rating by SunTrust given on Thursday, November 2. The stock has “Hold” rating by Stifel Nicolaus on Friday, August 4. The rating was initiated by Compass Point with “Neutral” on Friday, April 15.

Since January 8, 2018, it had 0 insider purchases, and 2 selling transactions for $1.44 million activity. $1.09 million worth of stock was sold by Farah Jean Claude on Monday, January 8. 15,600 The Western Union Company (NYSE:WU) shares with value of $343,044 were sold by Schenkel Amintore.

Investors sentiment decreased to 0.81 in Q1 2018. Its down 0.26, from 1.07 in 2017Q4. It dived, as 35 investors sold WU shares while 196 reduced holdings. 56 funds opened positions while 131 raised stakes. 470.54 million shares or 1.44% more from 463.88 million shares in 2017Q4 were reported. Toth Finance Advisory Corporation holds 1,150 shares. State Of Alaska Department Of Revenue invested in 0.04% or 90,016 shares. Paloma Prns Management Com accumulated 82,762 shares or 0.03% of the stock. Ariel Invests Ltd Liability Corporation has invested 0.91% in The Western Union Company (NYSE:WU). Curbstone Financial Mngmt holds 20,500 shares. Asset One Ltd reported 778,245 shares. Global X Mgmt Ltd Liability reported 44,231 shares. 22,979 were accumulated by Bnp Paribas Asset. Nikko Asset Mngmt Americas Inc stated it has 0.08% in The Western Union Company (NYSE:WU). Teachers Retirement Sys Of The State Of Kentucky has 46,717 shares for 0.01% of their portfolio. 87,446 are held by Dorsey Whitney Tru Co Limited Liability Corporation. Mufg Americas Hldgs holds 0% or 1,000 shares. M&T Bankshares owns 79,168 shares or 0.01% of their US portfolio. Fukoku Mutual Life Insurance invested in 7,867 shares. California Pub Employees Retirement holds 0.04% of its portfolio in The Western Union Company (NYSE:WU) for 1.57 million shares.

Analysts await The Western Union Company (NYSE:WU) to report earnings on August, 2. They expect $0.48 EPS, down 4.00% or $0.02 from last year’s $0.5 per share. WU’s profit will be $221.15 million for 10.82 P/E if the $0.48 EPS becomes a reality. After $0.45 actual EPS reported by The Western Union Company for the previous quarter, Wall Street now forecasts 6.67% EPS growth.

The Western Union Company (NYSE:WU) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>